<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03801447</url>
  </required_header>
  <id_info>
    <org_study_id>DAC-003-REPORTS</org_study_id>
    <nct_id>NCT03801447</nct_id>
  </id_info>
  <brief_title>Biomarkers and Preeclampsia Outcomes</brief_title>
  <acronym>REPORTS</acronym>
  <official_title>Ratio of Angiogenesis-related Biomarkers (sFlt-1/PlGF) in the Prediction Of mateRnal &amp; feTal outcomeS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dacima Consulting</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternity Center of Tunis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dacima Consulting</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational, monocentric, non-interventional study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In practice, patients with preeclampsia are referred to the hospital for medical management
      only clinical signs &amp; symptoms and standard biological tests are available for patient
      individualized care. Hence, a new diagnostic tool to distinguish and stratify the different
      patients referred is in need of proper triage.

      REPORTS study aims to determine the diagnostic utility of 2 preeclampsia biomarkers
      (sFlt-1/PlGF ratio) in clinical decision making in preeclamptic women.

      Data are collected by DACIMA Clinical Suite, according to FDA 21 CFR part 11 requirements
      (Food and Drug Administration 21 Code of Federal Regulations part 11), the HIPAA
      specifications (Health Insurance Portability and Accountability Act), and the ICH standards
      (International Conference on Harmonisation)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers ratio</measure>
    <time_frame>Every day from date of inclusion until date of delivery or up to 21 days whichever came first, in women with severe preeclampsia</time_frame>
    <description>sFlt-1/PlGF ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers ratio</measure>
    <time_frame>Every two day from date of inclusion until date of delivery or up to 21 days whichever came first, in women with moderate preeclampsia</time_frame>
    <description>sFlt-1/PlGF ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers ratio</measure>
    <time_frame>Weekly from date of inclusion until date of delivery or up to 3 weeks whichever came first, in women with mild preeclampsia</time_frame>
    <description>sFlt-1/PlGF ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal outcome</measure>
    <time_frame>From date of inclusion until the date of first documented event, assessed up to 24 weeks</time_frame>
    <description>Incidence of retroplacental hematoma, or HELLP syndrome (Hemolysis, Elevated liver enzyme levels, and Low Platelet levels), or Renal failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal outcome</measure>
    <time_frame>From date of inclusion until the date of first documented event, assessed up to 24 weeks</time_frame>
    <description>Incidence of a composite fetal outcome (in utero fetal death or, Intrauterine growth restriction, or APGAR &lt; 7, or Prematurity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal outcome</measure>
    <time_frame>Date of delivery</time_frame>
    <description>Rate of in utero fetal death or, Intrauterine growth restriction, or APGAR &lt; 7, or Prematurity</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Preeclampsia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Preeclampsia was defined according to the ACOG (The American College of Obstetricians and
        Gynecologists). The diagnosis of Preeclampsia was based on clinical judgment and routine
        laboratory findings at inclusion.

        Patients were suspected of Preeclampsia if they:

          -  presented with new onset hypertension and or proteinuria at or after 20 weeks of
             gestation

          -  developed an aggravation of their preexisting hypertension and or preexisting
             proteinuria

          -  or if they presented with symptoms such as right upper quadrant abdominal pain or
             headache with visual disturbances or PE-related findings (low platelets, elevated
             liver transaminases, Vascular Fetal Growth Restriction)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected or confirmed preeclampsia

          -  Singleton pregnancy

          -  Between 26 weeks of gestation and 37 weeks of gestation &amp; 6 days

        Exclusion Criteria:

          -  Multiple pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalenda Chelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maternité de la Rabta - Tunis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youcef Djedid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maternité de la Rabta - Tunis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dalenda Chelli, MD</last_name>
    <phone>+21622889018</phone>
    <email>dalenda.chelli@sted-tn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabie Razgallah, MD</last_name>
    <phone>+21620509729</phone>
    <email>r.razgallah@dacimasoftware.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternity Center of Tunis</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalenda Chelli, MD</last_name>
      <phone>+21622889018</phone>
      <email>dalenda.chelli@sted-tn.com</email>
    </contact>
    <contact_backup>
      <last_name>Rabie Razgallah, MD</last_name>
      <phone>+21620509729</phone>
      <email>r.razgallah@dacimasoftware.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 27, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

